Latest News
Opinion
Breastfeeding and colorectal cancer
Investigators examining the health histories of more than 150,000 women found that those who were breastfed incurred a 23% greater risk of...
Latest News
Seven metrics oncology practices can track to be successful
“Once practices figure out what they want to measure, and obviously they want to measure things that they’re not doing so well, they can look for...
Latest News
Experts question finding that 70% cancer deaths are preventable
The findings represent a snapshot of premature mortality in 2020 but do not necessarily predict progress in cancer control over time.
Conference Coverage
Neoadjuvant, adjuvant, or both? The debate in NSCLC rages on
The question of whether to give upfront immunochemotherapy in resectable non–small cell lung cancer, wait until after surgery, or give both...
Conference Coverage
Rare lymphomas: Desperately seeking new txs
Experts seek global collaboration to develop novel therapies for peripheral T-cell lymphomas, a rare form of non-Hodgkin lymphoma with many...
Conference Coverage
‘We finally made it’: Amivantamab comes of age in NSCLC
Data from three trials with amivantamab in advanced EGFR-mutant NSCLC have yielded “exciting” results with experts hailing the drug as standard of...
Latest News
Induction chemotherapy in first line improves survival for locally advanced cervical cancer
With similar results reported for pembrolizumab, a question has arisen about how to incorporate induction chemotherapy and pembrolizumab into a...
Conference Coverage
Ocular MALT lymphoma: Radiation reduces relapse
Mortality rates from early-stage ocular MALT lymphoma are low, with relapse rates lowered by radiation therapy.
Feature
Massive databases unleash discovery, but not so much in the U.S.
Vast medical databases have connected dots where smaller randomized trials could not. But the United States has a long way to go.
Conference Coverage
Frontline myeloma treatments: ASCT vs. CAR T
Experts debate whether CAR T-cell therapy could eventually replace autologous stem cell transplant (ASCT) as the standard of care for multiple...
Conference Coverage
Dato-DXd trumps chemo in advanced HR+/HER2– breast cancer
The antibody-drug conjugate datopotamab deruxtecan had better efficacy and safety than chemotherapy for patients with endocrine-resistant...